Payment overview · 2025
General Payments
$116.52
6 reported records · 4 companies
Healthcare provider profile · identity verified
Olga Freeman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1306848726
Verified facts
What the public records show
CMS Open Payments records show Olga Freeman, MD received $116.52 in general payments during 2025 across 6 reported records.
Inspire Medical Systems, Inc. accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $57.45 | 49.3% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.30 | 21.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.07 | 15.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.70 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.52 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $57.45 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 549 | 148 |
| Omeprazole | Omeprazole | 443 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 120 |
| Losartan Potassium | Losartan Potassium | 394 | 109 |
| Lisinopril | Lisinopril | 381 | 99 |
| Metformin Hcl | Metformin Hcl | 347 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 287 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 276 | 75 |
| Simvastatin | Simvastatin | 253 | 72 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 236 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 57 |
| Gabapentin | Gabapentin | 178 | 48 |
| Eliquis | Apixaban | 154 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 44 |
| Trazodone Hcl | Trazodone Hcl | 148 | 36 |
| Alendronate Sodium | Alendronate Sodium | 135 | 43 |
| Buspirone Hcl | Buspirone Hcl | 135 | 33 |
| Sertraline Hcl | Sertraline Hcl | 134 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 38 |
| Ezetimibe | Ezetimibe | 116 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 31 |
| Jardiance | Empagliflozin | 112 | 27 |
| Bupropion Xl | Bupropion Hcl | 111 | 31 |
| Carvedilol | Carvedilol | 110 | 31 |
| Alprazolam | Alprazolam | 99 | 22 |
| Prednisone | Prednisone | 93 | 32 |
| Torsemide | Torsemide | 92 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 21 |
| Xarelto | Rivaroxaban | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 82 | 28 |
| Atenolol | Atenolol | 81 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 19 |
| Lorazepam | Lorazepam | 73 | 12 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Allopurinol | Allopurinol | 71 | 21 |
| Ozempic | Semaglutide | 69 | 13 |
| Tramadol Hcl | Tramadol Hcl | 68 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 19 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 35 |
| Famotidine | Famotidine | 56 | 17 |
| Propranolol Hcl | Propranolol Hcl | 56 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 16 |
| Valsartan | Valsartan | 54 | 15 |
| Finasteride | Finasteride | 53 | 17 |
| Temazepam | Temazepam | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 11 |
| Doxepin Hcl | Doxepin Hcl | 44 | 14 |
| Lovastatin | Lovastatin | 44 | 12 |
| Chlorthalidone | Chlorthalidone | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 42 | 14 |
| Glimepiride | Glimepiride | 39 | 11 |
| Meloxicam | Meloxicam | 39 | 15 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Prolia | Denosumab | 29 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 18 |
| Azithromycin | Azithromycin | 20 | 17 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Cholestyramine Light | Cholestyramine | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 15 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Yuvafem | Estradiol | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.52 · 6 records | Inspire Medical Systems, Inc. | GEMTESA, INSPIRE, SHINGRIX, Tymlos | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error